



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Chest Infections

SESSION TITLE: Medical Student/Resident Chest Infections Posters

SESSION TYPE: Med Student/Res Case Rep Poster

PRESENTED ON: October 18-21, 2020

A CASE OF COVID-19-ASSOCIATED ACUTE LIMB ISCHEMIA

AMANDA VAN MECL VIVIANA PAZ ELSY NAVAS AND IFTEKHAR BAIG

INTRODUCTION: Coronavirus Disease of 2019 (COVID19) is a novel coronavirus declared a pandemic in March 2020 by the World Health Organization. Research is finding that it is an inflammatory and coagulopathic infection, predisposing to thrombotic events even with thromboprophylaxis. We describe a COVID19-positive patient who developed acute limb ischemia.

CASE PRESENTATION: 54-year-old female with OSA, COPD and hypertension presented to the ER with fever, shortness of breath of 7 days. COVID19 PCR was positive. After marked D-dimer elevation, the decision was made to escalate VTE prophylaxis to therapeutic enoxaparin. After refusing doses she developed acute right lower extremity paresthesia and pain. Distal pulses were nonpalpable, fleeting by doppler. Arterial ultrasound suggested proximal arterial occlusion. Heparin drip was started, inflammatory markers and d-dimer improved. A contingency plan for loss of pulses was to utilize alteplase infusion via right femoral arterial line but never required. She developed severe ARDS requiring intubation with proning. She improved, underwent tracheostomy and weaned from ventilation. With negative COVID19 PCRs, peripheral angiography found occlusions of the right popliteal, proximal anterior tibial, peroneal arteries, with chronic posterior tibial occlusion. After thrombectomy and angioplasty, patency with two vessel run-off was achieved, oral anticoagulation started and she was discharged to LTACH.

DISCUSSION: Acute limb ischemia is a vascular emergency that threatens limb viability. Literature review suggests that COVID19 patients are predisposed to thrombotic events due to cytokine storm, stasis, hypoxia, endothelial dysfunction. Multiple retrospective analyses have demonstrated similar incidents of thrombosis ranging from 12-31%. A minority of these events are arterial. D-dimer, platelets, ferritin, IL-6 and LDH correlate with cytokine storm and procoagulant state. Elevated D-dimer levels are an independent predictor of mortality, have strong correlation with complications and are a tool to aid in the decision to escalate standard prophylaxis to therapeutic anticoagulation. Current prophylaxis recommendations include daily unfractionated or low molecular weight heparin. Aggressive prophylactic dosing has been suggested in these patients but clinical benefit has not been confirmed. Research in China has suggested these doses may reduce mortality in severe COVID19 infection by decreasing systemic inflammation early in the illness.

CONCLUSIONS: COVID19 has been shown to be high risk for both arterial and venous thromboembolism. Clinicians should assess therapeutic anticoagulation and lab values such as D-dimer may help with the decision. Given the infectivity of COVID19, precautions must be made to limit unnecessary exposure where possible, as in this case where peripheral intervention was only performed once the patient had completed her treatment course.

Reference #1: Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg* 2007; 45 Suppl S:S5.

Reference #2: Bikdeli, B., Madhavan, M.V., Jimenez, D., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. *Journal of the American College of Cardiology*. (2020, April 15). doi:10.1016/j.jacc.2020.04.031

Reference #3: Cui S., Chen S., Li X., et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J. Thromb. Haemost.* 2020 doi: 10.1111/jth.14830.

DISCLOSURES: No relevant relationships by Iftekhar Baig, source=Web Response

No relevant relationships by Elsy Navas, source=Web Response

No relevant relationships by Viviana Paz, source=Web Response

No relevant relationships by Amanda Van Mecl, source=Web Response

DOI: <http://dx.doi.org/10.1016/j.chest.2020.08.520>

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.